Skip to main content
. Author manuscript; available in PMC: 2013 Jun 1.
Published in final edited form as: J Antibiot (Tokyo). 2012 Oct 10;65(12):593–598. doi: 10.1038/ja.2012.77

Figure 2.

Figure 2

Time-kill kinetics of nosiheptide against MRSA and VRE. Nosiheptide killing kinetics was studied against MRSA and VRE at multiples of their MICs (MIC = 0.06 mg/L for nosiheptide). A.) Killing kinetics of nosiheptide at 1X, 10X, and 20X MIC against MRSA USA300 strain TCH1516 (MIC = 0.06 mg/L). B.) Nosiheptide killing kinetics against various multi-drug resistant MRSA at 10X their respective MICs. C.) Nosiheptide activity over time against VRE-CUS at multiples of the MIC (MIC = 0.125 mg/L). D.) Nosiheptide time-kill kinetics against MRSA USA300 strain TCH1516 compared to vancomycin at 10X and 20X their respective MICs (MIC = 0.06 mg/L for nosiheptide; MIC = 1.56 mg/L for vancomycin). Each assay was repeated in duplicate (for VRE) or triplicate (for MRSA), and the data shown are the mean +/− SD from one representative experiment.